| __timestamp | Halozyme Therapeutics, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 8494000000 |
| Thursday, January 1, 2015 | 93236000 | 9046000000 |
| Friday, January 1, 2016 | 150842000 | 9095000000 |
| Sunday, January 1, 2017 | 150643000 | 10554000000 |
| Monday, January 1, 2018 | 150252000 | 10775000000 |
| Tuesday, January 1, 2019 | 140804000 | 11355000000 |
| Wednesday, January 1, 2020 | 34236000 | 12340000000 |
| Friday, January 1, 2021 | 35672000 | 14277000000 |
| Saturday, January 1, 2022 | 66607000 | 14135000000 |
| Sunday, January 1, 2023 | 76363000 | 15048000000 |
| Monday, January 1, 2024 | 79048000 | 17232000000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Johnson & Johnson has consistently outpaced Halozyme Therapeutics, Inc. in R&D investment. From 2014 to 2023, Johnson & Johnson's R&D expenses grew by approximately 77%, reaching a peak in 2023. In contrast, Halozyme's R&D spending fluctuated, peaking in 2016 and then declining by nearly 50% by 2020. This disparity highlights Johnson & Johnson's robust focus on innovation, investing significantly more in R&D compared to Halozyme. As the industry faces new challenges and opportunities, these investments could be pivotal in shaping future breakthroughs. The data underscores the importance of sustained R&D efforts in maintaining a competitive edge and driving pharmaceutical advancements.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Strategic Focus on R&D Spending
Johnson & Johnson vs Merck & Co., Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Johnson & Johnson vs Bristol-Myers Squibb Company
Research and Development Investment: Johnson & Johnson vs Pfizer Inc.
Who Prioritizes Innovation? R&D Spending Compared for Johnson & Johnson and Zoetis Inc.
Research and Development Investment: Johnson & Johnson vs Catalyst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Johnson & Johnson and Celldex Therapeutics, Inc.
GSK plc or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
R&D Insights: How Summit Therapeutics Inc. and Halozyme Therapeutics, Inc. Allocate Funds
Research and Development Investment: Halozyme Therapeutics, Inc. vs PTC Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending